GENOMEWEB | NEW YORK – Day Zero Diagnostics said on Thursday that it has been granted an additional $8.2 million in funding from the Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator, or CARB-X, a global nonprofit organization.